Last reviewed · How we verify
Treatment H
Treatment H is a Small molecule drug developed by AstraZeneca. It is currently FDA-approved.
Treatment H is not a recognized or publicly documented AstraZeneca drug product.
Treatment H involves the use of L-Carnitine, specifically in the management of acute Clozapine intoxication, as per the study "The Efficacy of L-Carnitine in the Management of Acute Clozapine Intoxication" (NCT05632094).
At a glance
| Generic name | Treatment H |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Without a brand name or additional identifying information, 'Treatment H' cannot be matched to a specific marketed pharmaceutical product. This appears to be either a placeholder designation, an internal code name, or a non-existent drug.
Approved indications
Common side effects
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) (PHASE2)
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (PHASE2)
- Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma (PHASE1)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment H CI brief — competitive landscape report
- Treatment H updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Treatment H
What is Treatment H?
How does Treatment H work?
Who makes Treatment H?
What development phase is Treatment H in?
Related
- Manufacturer: AstraZeneca — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing